Mark Jacobson, MD

Headshot of Mark Jacobson
User Profile Photo

Mark Jacobson, MD

User Profile Name
Emeritus CFAR Mentor
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Dr. Jacobson is a clinician, educator, and researcher who has specialized in HIV/AIDS and its complications since joining the UCSF faculty in 1986. His earlier career involved leading multicenter, interventional trials that focused on developing effective treatments for AIDS-associated opportunistic infections. His subsequent research was translational, investigating protective immunity against chronic viral infections, in particular cytomegalovirus (CMV), HIV, and human papillomavirus (HPV). He now teaches medicine residents and medical students, provides clinical care and directs urgent care medical services for the Ward 86 HIV clinic at San Francisco General Hospital, and is the editor for the Ward 86 Medical Management Recommendations posted on UCSF’s HIV InSite website. Dr. Jacobson is also the author of Sensing Light, a novel about the unfolding of the AIDS epidemic in 1980s San Francisco from the perspective of front-line, treating physicians (see http://markajacobsonauthor.com/). In March, 2020, Dr. Jacobson was redeployed to Occupational Medicine division and in July, 2020, moved from the HIV/ID division to the Occupational Medicine, where he serves as the infectious diseases consultant for a team of MDs, NPs and RNs who manage employee COVID-19 health issues for all SF Department of Public Health facilities, including SF General Hospital. He currently staffs the Occupational Health Service COVID-19 and Vaccine Hotlines, has created and updates Hotline provider standard work guidance for testing/off-return to work decisions/management of COVID-19 vaccine adverse events, teaches Hotline providers, consults with Occupational Medicine leadership re policy changes and special issues that arise, and oversees a Vaccine Hotline, which he helped develop in December, 2020, for management of employees experiencing adverse effects of COVID-19 vaccination.
CTSI Profile Bio

Displaying 101 - 125 of 136

  1. Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr. 1992; 5 Suppl 1:S11-7.
  2. Jacobson MA, Fusaro RE, Galmarini M, Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J Infect Dis. 1991 Nov; 164(5):864-8.
  3. Jacobson MA, Hopewell PC, Yajko DM, Hadley WK, Lazarus E, Mohanty PK, Modin GW, Feigal DW, Cusick PS, Sande MA. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis. 1991 Nov; 164(5):994-8.
  4. Harb GE, Bacchetti P, Jacobson MA. Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS. 1991 Aug; 5(8):959-65.
  5. Jacobson MA, Mills J, Rush J, Peiperl L, Seru V, Mohanty PK, Hopewell PC, Hadley WK, Broadus VC, Leoung G. Morbidity and mortality of patients with AIDS and first-episode Pneumocystis carinii pneumonia unaffected by concomitant pulmonary cytomegalovirus infection. Am Rev Respir Dis. 1991 Jul; 144(1):6-9.
  6. Jacobson MA, Drew WL, Feinberg J, O'Donnell JJ, Whitmore PV, Miner RD, Parenti D. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis. 1991 Jun; 163(6):1348-51.
  7. Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab. 1991 May; 72(5):1130-5.
  8. Jacobson MA, Besch CL, Child C, Hafner R, Muth K, Deyton L. Clinical programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis. 1991 Mar; 10(3):195-8.
  9. Jacobson MA, Bacchetti P, Kolokathis A, Chaisson RE, Szabo S, Polsky B, Valainis GT, Mildvan D, Abrams D, Wilber J. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ. 1991 Jan 12; 302(6768):73-8.
  10. Jacobson MA, O'Donnell JJ. Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. J Acquir Immune Defic Syndr. 1991; 4 Suppl 1:S11-5.
  11. Wilcox CM, Diehl DL, Cello JP, Margaretten W, Jacobson MA. Cytomegalovirus esophagitis in patients with AIDS. A clinical, endoscopic, and pathologic correlation. Ann Intern Med. 1990 Oct 15; 113(8):589-93.
  12. Wilcox CM, Byford BA, Forsmark CE, Hadley WK, Cello JP, Jacobson MA. Campylobacter-like organisms are uncommon pathogens in patients infected with the human immunodeficiency virus. J Clin Microbiol. 1990 Oct; 28(10):2370-1.
  13. Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Busch D, Gordon S, Jacobson MA, Volberding PA. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med. 1990 Sep 20; 323(12):769-75.
  14. Farese RV, Schambelan M, Hollander H, Stringari S, Jacobson MA. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med. 1990 Jun 15; 112(12):955-6.
  15. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion. 1990 Feb; 30(2):133-7.
  16. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA, Gambertoglio JG. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1990 Jan 26; 525(1):133-40.
  17. Jacobson MA, O'Donnell JJ, Rousell R, Dionian B, Mills J. Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study. Antimicrob Agents Chemother. 1990 Jan; 34(1):176-8.
  18. Jacobson MA, Abrams DI, Volberding PA, Bacchetti P, Wilber J, Chaisson RE, Crowe S, Howard W, Moss A. Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine. J Infect Dis. 1989 Jun; 159(6):1029-36.
  19. Erlich KS, Jacobson MA, Koehler JE, Follansbee SE, Drennan DP, Gooze L, Safrin S, Mills J. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med. 1989 May 01; 110(9):710-3.
  20. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1989 May; 33(5):736-41.
  21. Aweeka F, Gambertoglio J, Mills J, Jacobson MA. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother. 1989 May; 33(5):742-5.
  22. O'Donnell JJ, Jacobson MA. Cotton-wool spots and cytomegalovirus retinitis in AIDS. Int Ophthalmol Clin. 1989; 29(2):105-7.
  23. Small PM, McPhaul LW, Sooy CD, Wofsy CB, Jacobson MA. Cytomegalovirus infection of the laryngeal nerve presenting as hoarseness in patients with acquired immunodeficiency syndrome. Am J Med. 1989 Jan; 86(1):108-10.
  24. Jacobson MA, McGrath MS, Joseph P, Molaghan JB, Tadepalli S, Quinn R. Zidovudine-induced fever. J Acquir Immune Defic Syndr. 1989; 2(4):382-8.
  25. Jacobson MA, Crowe S, Levy J, Aweeka F, Gambertoglio J, McManus N, Mills J. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis. 1988 Oct; 158(4):862-5.